Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reference values for left ventricular dimensions, systolic and diastolic function: a study from the Amazon Basin of Brazil

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Transesophageal and intracardiac echocardiography to guide transcatheter tricuspid valve repair with the TriClip™ system

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Three decades of heart transplantation: experience and long-term outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early Coronary Atherosclerosis in Women With Previous Preeclampsia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

To investigate the effects of 13 weeks treatment with empagliflozin in patients with high-risk type-2 diabetes mellitus on echocardiographic measures of left ventricular (LV) structure and function compared to placebo. A total of 91 patients were randomized to treatment with empagliflozin (25 mg/day, n = 45) or matching placebo (n = 45) for 13 weeks. Left ventricular (LV) mass, volumes and geometry as well as measures of LV systolic and diastolic function were measured using echocardiography at baseline and follow up. Mean LV mass index (LVMi) was reduced by - 11.5 g/m2 (95% CI - 56.4; 33.4, p = 0.03) with empagliflozin compared to - 1.4 g/m2 (95% CI - 36.5; 33.8, p = 0.63) for placebo. The proportion of patients with LV hypertrophy was reduced by 16.3% (p = 0.04) in the empagliflozin group compared to 1.1% in the placebo group (p = 1.00). The proportion of patients with left atrial volume index > 34 mL/m2 was reduced by 20.0% (p = 0.02) with empagliflozin compared to 9.5% for placebo (p = 0.45) and the E/e' ratio decreased (∆-0.8 (1.9) vs. ∆0.5 (2.0), p < 0.01). 13 weeks empagliflozin treatment in patients with type-2 diabetes at high CV risk significantly reduced LV mass, improved LV geometry and improved diastolic function compared to placebo.

Original languageEnglish
JournalThe international journal of cardiovascular imaging
Volume38
Issue number3
Pages (from-to)579-587
Number of pages9
ISSN1569-5794
DOIs
Publication statusPublished - Mar 2022

Bibliographical note

© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

    Research areas

  • Echocardiography, Left ventricular hypertrophy, SGLT2i, Type-2 diabetes

ID: 69614509